Bing L Lin

US Patent:

20100105620, Apr 29, 2010

Filed:

Oct 9, 2009

Appl. No.:

12/577067

Inventors:

Katherine S. Bowdish - Del Mar CA, US
Mark Renshaw - San Diego CA, US
Bing Lin - San Diego CA, US
Martha Wild - San Deigo CA, US

International Classification:

A61K 38/16
C07K 14/00
C07K 7/08
C07H 21/04
C12N 15/63
C12N 5/00
G01N 33/53
C40B 30/04

US Classification:

514 12, 530324, 530327, 536 231, 4353201, 435325, 435 71, 506 9

Abstract:

Agonists for TRAIL death receptors including polypeptides having a multimerizing, e.g. trimerizing, domain and a polypeptide sequence that binds to at least one of TRAIL death receptors TRAIL-R1 and TRAIL-R2. Agonists are described that do not bind to TRAIL decoy receptors. The multimerizing domain may be derived from human tetranectin. The agonists can induce apoptosis in pathogenic cells expressing a TRAIL death receptor. Pharmaceutical compositions are described for treating diseases associated with cells expressing DR4 and DR5, such as tumor cells. Methods for selecting polypeptides and preparing multimeric complexes.

US Patent:

20120021995, Jan 26, 2012

Filed:

Jul 26, 2011

Appl. No.:

13/190914

Inventors:

Katherine Bowdish - Del Mar CA, US
Mark Renshaw - San Diego CA, US
Bing Lin - San Diego CA, US
Jean de Silva Correia - San Diego CA, US
Roger Ferrini - San Diego CA, US
Elise Chen - Del Mar CA, US

Assignee:

ANAPHORE, INC. - La Jolla CA

International Classification:

A61K 38/16
A61P 35/00
A61K 38/10
C07K 7/04
C07K 14/00

US Classification:

514 193, 530326, 530324

Abstract:

Agonists for TRAIL death receptors including polypeptides that bind to TRAIL death receptor TRAIL-R1 (DR4) and/or TRAIL-R2 (DR5) and optionally having a multimerizing, e.g. trimerizing domain. Agonists are described that do not bind to TRAIL decoy receptors. The multimerizing domain may be derived from human tetranectin. The agonists can induce apoptosis in pathogenic cells expressing a TRAIL death receptor. Pharmaceutical compositions are described for treating diseases associated with cells expressing DR4 and DR5, such as tumor cells. Methods for selecting polypeptides and preparing multimeric complexes.

US Patent:

20120135938, May 31, 2012

Filed:

Jan 26, 2012

Appl. No.:

13/359211

Inventors:

Katherine S. Bowdish - del Mar CA, US
Mark Renshaw - San Diego CA, US
Bing Lin - San Diego CA, US
Martha Wild - San Diego CA, US

Assignee:

ANAPHORE, INC. - La Jolla CA

International Classification:

A61K 38/17
C12N 15/62
A61P 35/00
C12N 1/21
C12N 5/10
C07K 19/00
C12N 15/63

US Classification:

514 189, 530300, 530350, 536 234, 4353201, 43525233, 435369, 435358, 435368

Abstract:

Agonists for TRAIL death receptors including polypeptides having a multimerizing, e.g. trimerizing, domain and a polypeptide sequence that binds to at least one of TRAIL death receptors TRAIL-R1 and TRAIL-R2. Agonists are described that do not bind to TRAIL decoy receptors. The multimerizing domain may be derived from human tetranectin. The agonists can induce apoptosis in pathogenic cells expressing a TRAIL death receptor. Pharmaceutical compositions are described for treating diseases associated with cells expressing DR4 and DR5, such as tumor cells. Methods for selecting polypeptides and preparing multimeric complexes.